Susquehanna International Group
STLN

Susquehanna International Group’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Susquehanna International Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$285K Sell
92,869
-202,281
-69% -$620K ﹤0.01% 10972
2025
Q4 		$1.05M Buy
+295,150
New +$1.09M ﹤0.01% 7069
2025
Q3 		– Sell
-113,676
Closed -$389K – 13895
2025
Q2 		$233K Buy
113,676
+91,288
+408% +$228K ﹤0.01% 10901
2025
Q1 		$25.5K Buy
+22,388
New +$17.3K ﹤0.01% 12056
2024
Q4 		– Sell
-34,411
Closed -$11.2K – 13230
2024
Q3 		$11.2K Buy
34,411
+3,229
+10% +$1.34K ﹤0.01% 11710
2024
Q2 		$14.3K Buy
+31,182
New +$26.6K ﹤0.01% 11725
2023
Q2 		– Sell
-44,019
Closed -$29.8K – 13144
2023
Q1 		$29.8K Buy
+44,019
New +$56.2K ﹤0.01% 11912
2022
Q4 		– Sell
-10,525
Closed -$49K – 13679
2022
Q3 		$49K Buy
+10,525
New +$61.9K ﹤0.01% 12222

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's STLN Position: Q1 2026 in Review

Susquehanna International Group reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 69% in Q1 2026, selling an estimated $620K and leaving 92,869 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #10972.

Susquehanna International Group first reported a position in STLN in Q3 2022 and has held it in 8 quarters since. The position peaked at $1.05M in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Susquehanna International Group held 92,869 shares of Starling Oncology Institute, Inc. Common Stock worth $285K as of Q1 2026.
  • Susquehanna International Group sold 202,281 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $620K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10972 holding.
  • Susquehanna International Group first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2022 and has held it in 8 quarters since.
  • Susquehanna International Group's Starling Oncology Institute, Inc. Common Stock position peaked at $1.05M in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.